Hangzhou Tigermed Equity Investment Partnership

Overview

Hangzhou Tigermed Equity Investment Partnership is a private equity firm specializing in the healthcare and biotechnology sectors. The firm is a subsidiary of Hangzhou Tigermed Consulting Co., Ltd., a global Contract Research Organization (CRO) headquartered in Hangzhou, China. Tigermed Consulting is listed on both the Shenzhen Stock Exchange (stock code: 300347) and the Stock Exchange of Hong Kong (stock code: 3347). The firm's investment strategy encompasses various stages, including early-stage, growth, late-stage, pre-IPO, and buyout investments. It focuses on a wide geographical area, with investments in China, South Korea, Hong Kong, Australia, Malaysia, Singapore, the United States, Taiwan, India, Canada, Japan, the United Kingdom, Brazil, Mexico, South Africa, Colombia, Peru, Chile, Argentina, and the Netherlands. The industries targeted by the firm include healthcare, biotechnology, medical devices, pharmaceuticals, clinical research, medical services, medical information technology, digital therapy, intelligent manufacturing, medical equipment, CRO, new drugs, and medical equipment. As of December 31, 2024, Hangzhou Tigermed Equity Investment Partnership held a 50% equity interest in Hangzhou Taikun, a fund established in August 2021 with a registered capital of RMB20 billion. Hangzhou Taikun focuses on innovative start-ups in the healthcare industry, making both direct strategic investments and investments in equity and venture capital funds within the sector. The firm's investment in Hangzhou Taikun amounted to RMB3,000 million as of December 31, 2024, accounting for 5.6% of the total assets of the Group. This investment aligns with Tigermed's long-term strategy to enhance its position in the biopharmaceutical field and optimize the upstream and downstream industrial chain, thereby strengthening its core competitiveness. In addition to its investments in Hangzhou Taikun, Tigermed has made significant investments in other healthcare-related companies. For instance, in 2015, the company acquired a 98.14% stake in DreamCIS Inc., a leading clinical research organization in South Korea, for approximately $26 million. This acquisition expanded Tigermed's global presence and capabilities in clinical research services. The firm's diverse portfolio reflects its commitment to advancing healthcare through strategic investments in innovative companies and technologies. Tigermed's investment philosophy emphasizes a comprehensive approach to the healthcare sector, targeting various stages of company development and a broad range of industries. This strategy enables the firm to support a diverse array of companies, from early-stage start-ups to established enterprises, contributing to the growth and advancement of the global healthcare industry. The firm's global presence is further demonstrated by its investments in multiple countries, including the United States, South Korea, Hong Kong, Australia, Malaysia, Singapore, Taiwan, India, Canada, Japan, the United Kingdom, Brazil, Mexico, South Africa, Colombia, Peru, Chile, Argentina, and the Netherlands. This international footprint allows Tigermed to leverage a wide range of opportunities and resources, enhancing its ability to identify and support promising healthcare ventures worldwide. Tigermed's strategic investments and global expansion reflect its dedication to fostering innovation and excellence in the healthcare sector, aiming to improve patient outcomes and contribute to the advancement of medical science and technology. The firm's commitment to the healthcare industry is further evidenced by its substantial investments in various healthcare-related companies and funds, demonstrating its dedication to supporting the growth and development of the sector. Tigermed's investment activities are guided by a philosophy that combines strategic foresight with a deep understanding of the healthcare landscape, enabling the firm to make informed decisions that align with its long-ter

Investment Focus

• Focus on innovative healthcare and biotechnology companies
• Interest in both early-stage and established enterprises
• Alignment with Tigermed's strategic objectives in the healthcare sector
• Commitment to enhancing global healthcare through strategic investments

Portfolio Companies